Allen Frances on Why DSM-5′s New Diagnoses Aren’t Necessary
One of the most note-worthy changes in the DSM-5 is the abundance of new diagnoses that are included in this new edition. Many DSM-5 critics worry that this is an indication of the reckless power that Big Pharma has over the psychotherapy industry; more diagnoses means more opportunities to choose medication over talk therapy, which is the road more and more practitioners are pressured into taking in order to be reimbursed.
These criticisms have become so common that they may seem like fear mongering. But it’s hard to dismiss the potential problems with the DSM-5 when one of its foremost critics, Allen Frances, served as Chair of the DSM-IV Task Force.
In this video clip from our Networker Webcast series The Uproar Over DSM-5, Allen talks about the diagnosis selection process he used in DSM-IV, and how limiting the addition of new diagnoses managed to both maintain the integrity of psychotherapy and leave the pharmaceutical companies unharmed.
The Uproar Over DSM-5:
How The New Standards Affect Your Practice
Get course details here.